Evidence map›Paper›PMID 24361467›Full record

ArticleGastroenterology2014

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

Yi Ni, Florian A Lempp, Stefan Mehrle, Shirin Nkongolo, Christina Kaufman, Maria Fälth, Jan Stindt, Christian Königer, Michael Nassal, Ralf Kubitz and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 429 papers.

0numbers the graph read from it
0cells of the map it votes in
429citing papers in PubMed
36.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

429 citing papers in PubMed, 753 citations in OpenAlex.

  1. Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Short-chain Fatty Acids and Bile Acids Signaling in Chronic Hepatitis B.Journal of clinical and translational hepatology · 2026
    Review
  10. Article
  11. Article
  12. Hepatitis B virus covalently closed circular DNA formation in murine hepatic cells uncovers a late entry block.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. [Construction of a highly efficient HBV infection cell model based on HBV co-receptor neuropilin-1].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  20. Article

369 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Yi NiDepartment of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Florian A LemppDepartment of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Stefan MehrleDepartment of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Shirin NkongoloDepartment of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Christina KaufmanDepartment of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Maria FälthGerman Cancer Research Center and National Center for Tumor Diseases, Unit Cancer Genome Research, Heidelberg, Germany.
Jan StindtClinic for Gastroenterology, Hepatology and Infectiology, University Hospital Düsseldorf, Düsseldorf, Germany.
Christian KönigerDepartment of Internal Medicine II, University Hospital Freiburg, Freiburg, Germany.
Michael NassalDepartment of Internal Medicine II, University Hospital Freiburg, Freiburg, Germany.
Ralf KubitzClinic for Gastroenterology, Hepatology and Infectiology, University Hospital Düsseldorf, Düsseldorf, Germany.
Holger SültmannGerman Cancer Research Center and National Center for Tumor Diseases, Unit Cancer Genome Research, Heidelberg, Germany.
Stephan UrbanDepartment of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany. Electronic address: Stephan.Urban@med.uni-heidelberg.de.
University Hospital Heidelberg · DEGerman Cancer Research Center · DEHeidelberg University · DEUniversity Medical Center Freiburg · DEDüsseldorf University Hospital · DEHeinrich Heine University Düsseldorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsHepatitis B and D viruses (HBV and HDV) are human pathogens with restricted host ranges and high selectivity for hepatocytes; the HBV L-envelope protein interacts specifically with a receptor on these cells. We aimed to identify this receptor and analyze whether it is the recently described sodium-taurocholate co-transporter polypeptide (NTCP), encoded by the SLC10A1 gene.

methodsTo identify receptor candidates, we compared gene expression patterns between differentiated HepaRG cells, which express the receptor, and naïve cells, which do not. Receptor candidates were evaluated by small hairpin RNA silencing in HepaRG cells; the ability of receptor expression to confer binding and infection were tested in transduced hepatoma cell lines. We used interspecies domain swapping to identify motifs for receptor-mediated host discrimination of HBV and HDV binding and infection.

resultsBioinformatic analyses of comparative expression arrays confirmed that NTCP, which was previously identified through a biochemical approach is a bona fide receptor for HBV and HDV. NTCPs from rat, mouse, and human bound Myrcludex B, a peptide ligand derived from the HBV L-protein. Myrcludex B blocked NTCP transport of bile salts; small hairpin RNA-mediated knockdown of NTCP in HepaRG cells prevented their infection by HBV or HDV. Expression of human but not mouse NTCP in HepG2 and HuH7 cells conferred a limited cell-type-related and virus-dependent susceptibility to infection; these limitations were overcome when cells were cultured with dimethyl sulfoxide. We identified 2 short-sequence motifs in human NTCP that were required for species-specific binding and infection by HBV and HDV.

conclusionsHuman NTCP is a specific receptor for HBV and HDV. NTCP-expressing cell lines can be efficiently infected with these viruses, and might be used in basic research and high-throughput screening studies. Mapping of motifs in NTCPs have increased our understanding of the species specificities of HBV and HDV, and could lead to small animal models for studies of viral infection and replication.

Indexed as

Virus InternalizationAnimalsBinding, CompetitiveComputational BiologyGene Expression ProfilingHepatitis B virusHepatitis Delta VirusHepatocytesHep G2 CellsHost-Pathogen InteractionsHumansLigandsLipopeptidesMiceOligonucleotide Array Sequence AnalysisOrganic Anion Transporters, Sodium-DependentLigandsLipopeptidesL protein, hepatitis B virusmyrcludex-BOrganic Anion Transporters, Sodium-Dependentsodium-bile acid cotransporterSymportersTaurocholic AcidViral Envelope ProteinsMyrcludex BSpecies SpecificityVirologyVirus Entry

Identifiers

PMID24361467
OpenAlexW2088160623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.